Increased serotonin transporter immunoreactivity intensity in the ileum of patients with irritable bowel disease

Wendelbo,Ingvild; Mazzawi,Tarek; El‑Salhy,Magdy

doi:10.3892/mmr.2013.1784

Increased serotonin transporter immunoreactivity intensity in the ileum of patients with irritable bowel disease

Authors:
- Ingvild Wendelbo
- Tarek Mazzawi
- Magdy El‑Salhy
View Affiliations

Affiliations: Section for Gastroenterology, Department of Medicine, Stord Helse‑Fonna Hospital, Stord 5416, Norway
Published online on: November 8, 2013 https://doi.org/10.3892/mmr.2013.1784
Pages: 180-184

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder, which represents an economic burden to society and considerably reduces the quality of life of patients. In a previous study, the density of serotonin cells in the ileum of IBS patients was lower compared with control subjects. The present study aimed to further investigate the immunoreactivity intensity of serotonin and serotonin‑selective reuptake transporter (SERT) in the ileum of IBS patients. A total of 98 patients (77 females and 21 males; mean age, 35 years; range, 18‑66 years), which fulfilled Rome III Criteria for IBS, were included in the study. This cohort included 35 patients with diarrhoea‑predominant (IBS‑D), 31 patients with mixed diarrhoea and constipation (M‑IBS) and 32 patients with constipation‑predominant (IBS‑C) symptoms. A total of 27 subjects were included as controls (16 females and 11 males; mean age, 52 years; range, 20‑69 years). Ileal biopsy specimens were immunostained using the avidin‑biotin (ABC) complex method for serotonin and SERT. The immunoreactivity intensity was quantified by computerised image analysis using Olympus cellSens imaging software. No statistical difference of serotonin immunoreactivity intensity was identified in multiple comparisons between controls, IBS‑total, IBS‑D, IBS‑M and IBS‑C. The SERT immunoreactivity intensity was significantly increased in IBS patients as compared with controls, regardless of the subtype. It was concluded that the increase in ileal epithelial content of SERT increases the intracellular uptake of serotonin and its degradation in the gut epithelial cells and consequently decreases the availability of serotonin within the gut mucosa. The low availability of serotonin at its receptors occurred in all IBS subtypes. This may indicate that this abnormality is associated with a common symptom in all IBS subtypes, namely abdominal pain/discomfort. Serotonin acts upon sensory neurons in the submucosal and myenteric ganglia, as well as in the spinal cord, which is in agreement with this hypothesis.

View Figures

View References

1	Thompson WG: A world view of IBS. Irritable Bowel Syndrome. Camilleri M and Spiller RC: Saunders; Philadelphia and London: pp. 17–26. 2002
2	Drossman DA, Li Z, Andruzzi E, et al: U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 38:1569–1580. 1993. View Article : Google Scholar : PubMed/NCBI
3	El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Irritable Bowel Syndrome: Diagnosis, Pathogenesis and Treatment Options. Nova Science Publishers; New York: 2012
4	Ford AC and Vandvik PO: Irritable bowel syndrome. Clin Evid (Online). 2012:04102012.
5	Lovell RM and Ford AC: Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 10:712–721. 2012. View Article : Google Scholar : PubMed/NCBI
6	Quigley EM, Locke GR, Mueller-Lissner S, et al: Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther. 24:411–419. 2006. View Article : Google Scholar : PubMed/NCBI
7	Vandvik PO, Lydersen S and Farup PG: Prevalence, comorbidity and impact of irritable bowel syndrome in Norway. Scand J Gastroenterol. 41:650–656. 2006. View Article : Google Scholar : PubMed/NCBI
8	Saito YA, Schoenfeld P and Locke GR III: The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 97:1910–1915. 2002.PubMed/NCBI
9	Whitehead WE, Burnett CK, Cook EW III and Taub E: Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 41:2248–2253. 1996. View Article : Google Scholar : PubMed/NCBI
10	Agréus L, Svärdsudd K, Nyrén O and Tibblin G: Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 109:671–680. 1995.PubMed/NCBI
11	Thompson WG and Heaton KW: Functional bowel disorders in apparently healthy people. Gastroenterology. 79:283–288. 1980.PubMed/NCBI
12	Kennedy TM, Jones RH, Hungin AP, O’flanagan H and Kelly P: Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 43:770–774. 1998. View Article : Google Scholar : PubMed/NCBI
13	Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR and Evans RW: Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 109:1736–1741. 1995. View Article : Google Scholar : PubMed/NCBI
14	Hungin AP, Whorwell PJ, Tack J and Mearin F: The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 17:643–650. 2003. View Article : Google Scholar : PubMed/NCBI
15	Jones R and Lydeard S: Irritable bowel syndrome in the general population. BMJ. 304:87–90. 1992. View Article : Google Scholar : PubMed/NCBI
16	Bordie AK: Functional disorders of the colon. J Indian Med Assoc. 58:451–456. 1972.PubMed/NCBI
17	O’Keefe EA, Talley NJ, Zinsmeister AR and Jacobsen SJ: Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci. 50:M184–M189. 1995.PubMed/NCBI
18	Everhart JE and Renault PF: Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 100:998–1005. 1991.PubMed/NCBI
19	Wilson S, Roberts L, Roalfe A, Bridge P and Singh S: Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 54:495–502. 2004.PubMed/NCBI
20	Harvey RF, Salih SY and Read AE: Organic and functional disorders in 2000 gastroenterology outpatients. Lancet. 1:632–634. 1983. View Article : Google Scholar : PubMed/NCBI
21	Spiegel BM: The burden of IBS: looking at metrics. Curr Gastroenterol Rep. 11:265–269. 2009. View Article : Google Scholar : PubMed/NCBI
22	Gralnek IM, Hays RD, Kilbourne A, Naliboff B and Mayer EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 119:654–660. 2000. View Article : Google Scholar : PubMed/NCBI
23	Drossman DA, Morris CB, Schneck S, et al: International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 43:541–550. 2009. View Article : Google Scholar
24	Sandler RS, Everhart JE, Donowitz M, et al: The burden of selected digestive diseases in the United States. Gastroenterology. 122:1500–1511. 2002. View Article : Google Scholar : PubMed/NCBI
25	Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F and Spiller RC: Functional bowel disorders. Gastroenterology. 130:1480–1491. 2006. View Article : Google Scholar : PubMed/NCBI
26	Drossman DA: Rome III: the new criteria. Chin J Dig Dis. 7:181–185. 2006. View Article : Google Scholar : PubMed/NCBI
27	Mawe GM, Coates MD and Moses PL: Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther. 23:1067–1076. 2006. View Article : Google Scholar : PubMed/NCBI
28	Erspamer V: Occurrence and distribution of 5-hydroxytryptamine (enteramine) in the living organism. Z Vitam Horm Fermentforsch. 9:74–96. 1957.PubMed/NCBI
29	Chen JX, Pan H, Rothman TP, Wade PR and Gershon MD: Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am J Physiol. 275:G433–G448. 1998.PubMed/NCBI
30	Spiller R and Lam C: An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil. 18:258–268. 2012. View Article : Google Scholar : PubMed/NCBI
31	Coates MD, Mahoney CR, Linden DR, et al: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 126:1657–1664. 2004. View Article : Google Scholar : PubMed/NCBI
32	El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Abnormal endocrine cells in the ileum of patients with irritable bowel syndrome. World J Gastroenterol. 2013.(In press).
33	El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG and Hausken T: Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci. 57:873–878. 2012. View Article : Google Scholar : PubMed/NCBI
34	El-Salhy M, Vaali K, Dizdar V and Hausken T: Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci. 55:3508–3513. 2010. View Article : Google Scholar : PubMed/NCBI
35	El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regul Pept. 2013.(In press).
36	Coates MD, Johnson AC, Greenwood-Van Meerveld B and Mawe GM: Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motil. 18:464–471. 2006. View Article : Google Scholar : PubMed/NCBI
37	El-Salhy M, Wendelbo I and Gundersen D: Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. Mol Med Rep. 8:451–455. 2013.PubMed/NCBI
38	Spiller R, Aziz Q, Creed F, et al: Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 56:1770–1798. 2007. View Article : Google Scholar : PubMed/NCBI
39	Keating C, Beyak M, Foley S, et al: Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism. J Physiol. 586:4517–4530. 2008. View Article : Google Scholar : PubMed/NCBI
40	Coleman NS, Foley S, Dunlop SP, et al: Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol. 4:874–881. 2006. View Article : Google Scholar : PubMed/NCBI
41	Camilleri M, Andrews CN, Bharucha AE, et al: Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology. 132:17–25. 2007. View Article : Google Scholar : PubMed/NCBI
42	Camilleri M, Busciglio I, Carlson P, et al: Candidate genes and sensory functions in health and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 295:G219–G225. 2008. View Article : Google Scholar : PubMed/NCBI
43	Kumar S, Ranjan P, Mittal B and Ghoshal UC: Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. J Gastrointestin Liver Dis. 21:31–38. 2012.PubMed/NCBI
44	Park JM, Choi MG, Park JA, et al: Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil. 18:995–1000. 2006. View Article : Google Scholar : PubMed/NCBI
45	Saito YA, Larson JJ, Atkinson EJ, et al: The role of 5-HTT LPR and GNβ3 825C>T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS). Dig Dis Sci. 57:2650–2657. 2012.
46	Colucci R, Blandizzi C, Bellini M, Ghisu N, Tonini M and Del Tacca M: The genetics of the serotonin transporter and irritable bowel syndrome. Trends Mol Med. 14:295–304. 2008. View Article : Google Scholar : PubMed/NCBI
47	Colucci R, Gambaccini D, Ghisu N, et al: Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome. PloS One. 8:e548312013. View Article : Google Scholar : PubMed/NCBI
48	Faure C, Patey N, Gauthier C, Brooks EM and Mawe GM: Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology. 139:249–258. 2010. View Article : Google Scholar : PubMed/NCBI
49	Kim HJ, Camilleri M, Carlson PJ, et al: Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut. 53:829–837. 2004. View Article : Google Scholar
50	Park CS and Uhm JH: Polymorphisms of the serotonin transporter gene and G-protein β3 subunit gene in Korean children with irritable bowel syndrome and functional dyspepsia. Gut Liver. 6:223–228. 2012.